Fig. 1
Clinical prognostic analysis of Chinese FL patients in the entire cohort and different subgroups. A, B 5-year progression-free survival (PFS, A) and overall survival (OS, B) of Chinese FL population in the whole cohort. C, D Kaplan–Meier curves of PFS (C) and OS (D) according to different rituximab administrations (no rituximab treatments (No R), first-line induction chemotherapies with rituximab (Ri), maintenance with rituximab (Rm), and Ri plus Rm regimens). E OS for patients with or without histological transformation (HT). F OS for patients with HT prior to or post-treatment